SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL

被引：0

作者：

Rovin, Brad ^{[1
]}

Barratt, Jonathan ^{[2
,3
]}

Murphy, Edward ^{[4
]}

Geletka, Rob ^{[4
]}

Komers, Radko ^{[4
]}

Perkovic, Vlado ^{[5
]}

机构：

[1] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA

[2] Univ Leicester, Leicester LE1 7RH, Leics, England

[3] Leicester Gen Hosp, Leicester, Leics, England

[4] Travere Therapeut Inc, San Diego, CA USA

[5] Univ New S Wales, Sydney, NSW 2052, Australia

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2024年 / 83卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

371

引用

页码：S114 / S114

页数：1

共 8 条

[1] Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs. Irbesartan (IRB) in Patients with Immunoglobulin A Nephropathy (IgAN)
Busch, Martin
[J]. INNERE MEDIZIN, 2024, 65 : S147 - S148
[2] SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IGA NEPHROPATHY (IGAN): FINDINGS FROM THE SPARTAN TRIAL
Cheung, Chee Kay
Nloody, Stephanie
Dhaun, Neeraj
Griffin, Sian
Howson, Alexandra
Komers, Radko
Mercer, Alex
Sayer, Matthew
Sinha, Smeeta
Willcocks, Lisa
Barratt, Jonathan
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S117 - S117
[3] SPARSENTAN (SPAR) VS IRBESARTAN (IRB) IN PATIENTS (PTS) WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): RESULTS FROM THE DUPLEX TRIAL
Rheault, Michelle
Trachtman, Howard
Murphy, Edward
Komers, Radko
[J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S123 - S123
[4] Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Rovin, Brad H.
Barratt, Jonathan
Heerspink, Hiddo J. L.
Alpers, Charles E.
Bieler, Stewart
Chae, Dong-Wan
Diva, Ulysses A.
Floege, Juergen
Gesualdo, Loreto
Inrig, Jula K.
Kohan, Donald E.
Komers, Radko
Kooienga, Laura Ann
Lafayette, Richard
Maes, Bart
Malecki, Robert
Mercer, Alex
Noronha, Irene L.
Oh, Se Won
Peh, Chen Au
Praga, Manuel
Preciado, Priscila
Radhakrishnan, Jai
Rheault, Michelle N.
Rote, William E.
Tang, Sydney C. W.
Tesar, Vladimir
Trachtman, Howard
Trimarchi, Hernan
Tumlin, James A.
Wong, Muh Geot
Perkovic, Vlado
[J]. LANCET, 2023, 402 (10417): : 2077 - 2090
[5] BASELINE CHARACTERISTICS OF ADULTS ENROLLED IN THE ONGOING PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL TRIAL OF SPARSENTAN FOR THE TREATMENT OF IMMUNOGLOBULIN A NEPHROPATHY (PROTECT)
Wong, Muh
Barratt, Jonathan
Komers, Radko
Mercer, Alex
Rosenberg, Noah
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I142 - I144
[6] DUPILUMAB PROVIDES EARLY AND SUSTAINED CLINICALLY MEANINGFUL RESPONSES IN A PHASE 3 TRIAL IN ADOLESCENTS WITH INADEQUATELYCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM THE OVERALL POPULATION AND IN A SUBGROUP OF PATIENTS NOT ACHIEVING IGA SCORES OF 0/1
Simpson, Eric L.
Blauvelt, Andrew
Guttman-Yassky, Emma
Gooderham, Melinda
Hussain, Iftikhar
Chen, Zhen
Levit, Noah A.
Chao, Jingdong
Rossi, Ana B.
Bansal, Ashish
[J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 54 - 54
[7] Dupilumab provides early and sustained clinically meaningful responses in a phase 3 trial in adolescents with inadequately controlled moderate-to-severe atopic dermatitis: Results from the overall population and in a subgroup of patients not achieving IGA scores of 0/1
Simpson, Eric L.
Blauvelt, Andrew
Guttman-Yassky, Emma
Gooderham, Melinda
Hussain, Iftikhar
Chen, Zhen
Levit, Noah A.
Rossi, Ana B.
[J]. ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (01) : 89 - 89
[8] Clinically meaningful improvements in cutaneous lesions and quality of life measures in patients with atopic dermatitis with greater pruritus reductions after treatment with 60 mg nemolizumab subcutaneously every 4 weeks: subgroup analysis from a phase 3, randomized, controlled trial
Kabashima, Kenji
Matsumura, Takayo
Hayakawa, Yoshiteru
Kawashima, Makoto
[J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)

← 1 →